BR0108954A - method for inhibiting cathepsin s, 4-amino-azepan-3-one compounds as protease inhibitors and use of these compounds in the preparation of medicament for the treatment of diseases. - Google Patents

method for inhibiting cathepsin s, 4-amino-azepan-3-one compounds as protease inhibitors and use of these compounds in the preparation of medicament for the treatment of diseases.

Info

Publication number
BR0108954A
BR0108954A BRPI0108954-4A BR0108954A BR0108954A BR 0108954 A BR0108954 A BR 0108954A BR 0108954 A BR0108954 A BR 0108954A BR 0108954 A BR0108954 A BR 0108954A
Authority
BR
Brazil
Prior art keywords
compounds
inhibition
treatment
azepan
amino
Prior art date
Application number
BRPI0108954-4A
Other languages
Portuguese (pt)
Inventor
Maxwell D Cummings
Robert W Marquis Jr
Yu Ru
Scott K Thompson
Daniel F Veber
Dennis S Yamashita
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of BR0108954A publication Critical patent/BR0108954A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/08—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D421/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms
    • C07D421/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)

Abstract

"MéTODO PARA INIBIR CATEPSINA S, COMPOSTOS DE 4-AMINO-AZEPAN-3-ONAS COMO INIBIDORES DE PROTEASE E USO DESTES COMPOSTOS NA PREPARAçãO DE MEDICAMENTO PARA O TRATAMENTO DE DOENçAS". A presente invenção fornece métodos que usam 4-amino-azepan-3-onas, como inibidores de catepsina S no tratamento de doenças, nas quais a catepsina S está implicada, especialmente o tratamento ou prevenção de doença auto-imune; tratamento ou prevenção de um estado doentio causado pela formação de lesões ateroscleróticas e complicações que advêm delas; e doenças que requerem inibição, para terapia, de uma resposta imune restrita a MHC classe II, inibição de uma resposta asmática, inibição de uma resposta alérgica, inibição de uma resposta imune contra órgão ou tecido transplantado, ou inibição da atividade de elastases em ateroma, e compostos inovadores para uso com eles."METHOD FOR INHIBITING CATHESIN S, 4-AMINO-AZEPAN-3-ONO COMPOUNDS AS PROTEASE INHIBITORS AND USE OF THESE COMPOUNDS IN PREPARING MEDICINE FOR DISEASE TREATMENT". The present invention provides methods using 4-amino-azepan-3-ones as cathepsin S inhibitors in the treatment of diseases in which cathepsin S is implicated, especially the treatment or prevention of autoimmune disease; treating or preventing a disease state caused by the formation of atherosclerotic lesions and complications arising therefrom; and diseases requiring inhibition for therapy of an MHC class II restricted immune response, inhibition of an asthmatic response, inhibition of an allergic response, inhibition of an immune response against transplanted organ or tissue, or inhibition of elastase activity in atheroma , and innovative compounds for use with them.

BRPI0108954-4A 2000-04-18 2001-04-17 method for inhibiting cathepsin s, 4-amino-azepan-3-one compounds as protease inhibitors and use of these compounds in the preparation of medicament for the treatment of diseases. BR0108954A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19849300P 2000-04-18 2000-04-18
US27381101P 2001-03-07 2001-03-07
PCT/US2001/012326 WO2001089451A2 (en) 2000-04-18 2001-04-17 Protease inhibitors

Publications (1)

Publication Number Publication Date
BR0108954A true BR0108954A (en) 2006-05-09

Family

ID=26893840

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0108954-4A BR0108954A (en) 2000-04-18 2001-04-17 method for inhibiting cathepsin s, 4-amino-azepan-3-one compounds as protease inhibitors and use of these compounds in the preparation of medicament for the treatment of diseases.

Country Status (17)

Country Link
EP (1) EP1278502A4 (en)
JP (1) JP2004526662A (en)
KR (1) KR20020089482A (en)
CN (1) CN1431904A (en)
AR (1) AR032319A1 (en)
AU (1) AU9050701A (en)
BR (1) BR0108954A (en)
CA (1) CA2406829A1 (en)
CO (1) CO5280088A1 (en)
CZ (1) CZ20023460A3 (en)
HK (1) HK1053785A1 (en)
HU (1) HUP0301781A2 (en)
IL (1) IL151087A0 (en)
MX (1) MXPA02010276A (en)
NO (1) NO20025005L (en)
PL (1) PL366040A1 (en)
WO (1) WO2001089451A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1401453A4 (en) * 2001-05-17 2005-04-06 Smithkline Beecham Corp Protease inhibitors
US20050030912A1 (en) * 2002-08-22 2005-02-10 Enikia L.L.C. Use of hybrid (HW/DSP/MCU/SW) architectures for powerline OFDM communication field
CN1708293A (en) 2002-09-24 2005-12-14 诺瓦提斯公司 S1p receptor agonist for treating demyelinate disease
AU2003273697A1 (en) * 2002-10-08 2004-05-04 Merck Frosst Canada Ltd 4-amino-azepan-3-one compounds as cathepsin k inhibitors useful in the treatment of osteoporosis
US7297714B2 (en) * 2003-10-21 2007-11-20 Irm Llc Inhibitors of cathepsin S
WO2007097720A2 (en) * 2006-02-21 2007-08-30 Agency For Science, Technology And Research Method and reagents for treating hepatic fibrosis and inflammation
JPWO2009054454A1 (en) * 2007-10-24 2011-03-03 国立大学法人 東京医科歯科大学 Modulator of signal transduction of Toll-like receptor containing cathepsin inhibitor as an active ingredient
EP3545953A1 (en) 2008-06-20 2019-10-02 Novartis AG Paediatric compositions for treating1 multiple sclerosis
LV15485B (en) * 2018-09-13 2020-06-20 Latvijas Organiskās Sintēzes Institūts Selenophene chromenone hydroxamic acids, their production and use in angiogenesis inhibition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518528A (en) * 1983-05-19 1985-05-21 Rasnick David W α Amino fluoro ketones
CA2122227A1 (en) * 1993-04-29 1994-10-30 Roland E. Dolle Peptide analogs as irreversible interleukin-1.beta. protease inhibitors
DZ2285A1 (en) * 1996-08-08 2002-12-25 Smithkline Beecham Corp Cysteine protease inhibitors.
TR200101869T2 (en) * 1998-12-23 2002-01-21 Smithkline Beecham Corporation Protease Inhibitors.
US7071184B2 (en) * 2000-03-21 2006-07-04 Smithkline Beecham Corporation Protease inhibitors
AU2001286983A1 (en) * 2000-09-01 2002-03-13 Smith Kline Beecham Corporation Method of treatment

Also Published As

Publication number Publication date
CN1431904A (en) 2003-07-23
IL151087A0 (en) 2003-04-10
CO5280088A1 (en) 2003-05-30
WO2001089451A3 (en) 2002-04-04
PL366040A1 (en) 2005-01-24
WO2001089451A2 (en) 2001-11-29
KR20020089482A (en) 2002-11-29
CZ20023460A3 (en) 2004-03-17
HK1053785A1 (en) 2003-11-07
NO20025005L (en) 2002-12-06
HUP0301781A2 (en) 2003-09-29
AR032319A1 (en) 2003-11-05
EP1278502A4 (en) 2003-05-21
EP1278502A2 (en) 2003-01-29
JP2004526662A (en) 2004-09-02
AU9050701A (en) 2001-12-03
NO20025005D0 (en) 2002-10-17
CA2406829A1 (en) 2001-11-29
MXPA02010276A (en) 2003-04-25

Similar Documents

Publication Publication Date Title
Rockwell Acute and chronic paronychia
BRPI0308663B8 (en) use of IL-18 inhibitors for the treatment and/or prevention of peripheral vascular diseases
WO2004029769A3 (en) A video game for assisting healing of the human body
PT1326613E (en) USE OF IMIDAZO [1,2-A] PYRIDIN-, IMIDAZO [1,2-A] PYRIMIDIN- AND IMIDAZO [1,2-A] PYRAZIN-3-IL-AMINE DERIVATIVES FOR THE MANUFACTURE OF MEDICINES FOR INHIBITION OF WE
BR0108954A (en) method for inhibiting cathepsin s, 4-amino-azepan-3-one compounds as protease inhibitors and use of these compounds in the preparation of medicament for the treatment of diseases.
BRPI0415713A (en) myo-inositol hexaphosphate for topical use
HK1080733A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
HUP0302718A2 (en) Methods and compositions for the treatment of diseases of the eye
BR0314081A (en) Combination therapy comprising a bisphosphonate and an hmg-coa reductase inhibitor
WO2004014367A3 (en) Use of an amyloid beta vaccination in combination with a selective cox-2 inhibitor for the treatment of alzheimer's disease
Smith The microcirculation in venous hypertension
BR0313081A (en) Combination of an aromatase inhibitor with a bisphosphanate
HUP0204097A2 (en) Use of guanosine-3',5'monophosphate phosphodiesteraze-inhibitor for production of pharmaceutical compositions available for treatment of diabetic ulcers
Thng et al. Thermal burns in diabetic feet
Belhorn et al. Atypical varicella exanthems associated with skin injury
Wilkel et al. Cyclosporine therapy for bullous erythema multiforme
Redwine Peritoneal blood painting: an aid in the diagnosis of endometriosis
BR0311180A (en) Methods for treating respiratory diseases and conditions using a selective inhibitor of inos
BR0209985A (en) Compound and method for treating a patient
Dams et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies
WO2007096596A3 (en) Use of il-8 for the treatment of crohn' s disease
Torkzaban et al. Smoking and periodontal diseases
Hwang et al. A pychoeducational group intervention for women with primary breast carcinoma
HEWITT et al. Recent trends in tetanus
Goldsmid, JM & Rogers A preliminary study on the treatment of filariasis due to Dipetalonema perstans

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 6A., 7A. E 8A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2008 DE 30/06/2009.